Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1683-1698

  Saruwatari, Junji ^a   Yasui Furukori, Norio ^b   Kamihashi, Ryoko ^a   Yoshimori, Yuki ^a   Oniki, Kentaro ^a   Tsuchimine, Shoko ^b   Noai, Madoka ^a   Sato, Yasushi ^c   Nakagami, Taku ^d   Sugawara, Norio ^b   Saito, Manabu ^b   Fujii, Akira ^b   Kajiwara, Ayami ^a   Mihara, Shuichi ^e   Ogata, Yasuhiro ^f   Kaneko, Sunao ^b   Nakagawa, Kazuko ^a,g  

^a KUMAMOTO UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Hirosaki Aiseikai Hospital   (Japan)

^d Odate Municipal General Hospital   (Japan)

^e Mihara life care clinic   (Japan)

^f JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Glutathione S transferase; Metabolic syndrome; Oxidative stress; Polymorphism; Schizophrenia; Superoxide dismutase 2

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; GLUTATHIONE TRANSFERASE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LEVOMEPROMAZINE; MANGANESE SUPEROXIDE DISMUTASE; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ELEVATED BLOOD PRESSURE; ENZYME POLYMORPHISM; FEMALE; GENE; GENOTYPE; GLUCOSE BLOOD LEVEL; GSTM1 GENE; GSTT1 GENE; HUMAN; JAPANESE; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SMOKING; SOD2 GENE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 84887137388     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S52585     Document Type: Article

References (46)

1. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25:83-88.
2. Srihari VH, Phutane VH, Ozkan B, et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophr Res. 2013;146:64-68.
3. Suttajit S, Pilakanta S. Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia. Neuropsychiatr Dis Treat. 2013;9:941-946.
4. Vancampfort D, Probst M, Scheewe T, et al. Relationships between physical ftness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia. Psychiatry Res. 2013; 207:25-32.
5. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114-126.
6. de Araujo AN, de Sena E P, de Oliveira IR, Juruena MF. Antipsychotic agents: efficacy and safety in schizophrenia. Drug Healthc Patient Saf. 2012;4:173-180.
7. Boden R, Edman G, Reutfors J, Ostenson CG, Osby U. A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat. 2013;9:371-377.
8. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68 Suppl 1:S20-S27.
9. Schorr SG, Slooff CJ, Bruggeman R, Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res. 2009;43:1106-1111.
10. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:14.
11. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289.
12. Spelman LM, Walsh PI, Sharif N, Collins P, Thakore JH. Impaired glucose tolerance in frst-episode drug-naive patients with schizophrenia. Diabet Med. 2007;24:481-485.
13. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009;70:997-1000.
14. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17:242-266.
15. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
17. Lear SA, Toma M, Birmingham CL, Frohlich JJ. Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism. 2003;52:1295-1301.
18. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27: 1182-1186.
19. Ruskovska T, Bernlohr DA. Oxidative stress and protein carbonyla-tion in adipose tissue - implications for insulin resistance and diabetes mellitus. J Proteomics. April 11, 2013. [Epub ahead of print.]
20. Codoner-Franch P, Valls-Belles V, Arilla-Codoner A, Alonso-Iglesias E. Oxidant mechanisms in childhood obesity: the link between inflammation and oxidative stress. Transl Res. 2011;158: 369-384.
21. Montero D, Walther G, Perez-Martin A, Roche E, Vinet A. Endothelial dysfunction, inflammation, and oxidative stress in obese children and adolescents: markers and effect of lifestyle intervention. Obes Rev. 2012;13:441-455.
22. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl. 2011;12: 267-270.
23. Kontush A, Chapman MJ. Functionally defective high-density lipopro-tein: a new therapeutic target at the crossroads of dyslipidemia, infam-mation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
24. Ginsberg G, Smolenski S, Hattis D, Guyton KZ, Johns DO, Sonawane B. Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B Crit Rev. 2009;12:389-439.
25. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51-88.
26. Ji JD, Lee WJ. Association between the polymorphisms of glutathione S-transferase genes and rheumatoid arthritis: a meta-analysis. Gene. 2013;521:155-159.
27. Hori M, Oniki K, Ueda K, et al. Combined glutathione S-transferase T1 and M1 positive genotypes afford protection against type 2 diabetes in Japanese. Pharmacogenomics. 2007;8:1307-1314.
28. Kariz S, Nikolajevic Starcevic J, Petrovic D. Association of manganese superoxide dismutase and glutathione S-transferases genotypes with myocardial infarction in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;98:144-150.
29. Santl Letonja M, Letonja M, Ikolajevic-Starcevic JN, Petrovic D. Association of manganese superoxide dismutase and glutathione S-transferases genotypes with carotid atherosclerosis in patients with diabetes mellitus type 2. Int Angiol. 2012;31:33-41.
30. Oniki K, Hori M, Saruwatari J, et al. Interactive effects of smoking and glutathione S-transferase polymorphisms on the development of non-alcoholic fatty liver disease. Toxicol Lett. 2013;220:143-149.
31. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15:1583-1606.
32. Sutton A, Imbert A, Igoudjil A, et al. The manganese superoxide dis-mutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics. 2005;15:311-319.
33. Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia. 2011;54:803-811.
34. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878-893.
35. Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:200-206.
36. Zhang X Y, Ya o JK. Oxidative stress and therapeutic implications in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:197-199.
37. Park YM, Lee HJ, Kang SG, Choi JE, Cho JH, Kim L. Lack of association between glutathione S-transferase-M1, -T1, and -P1 polymorphisms and olanzapine-induced weight gain in Korean schizophrenic patients. Psychiatry Investig. 2010;7:147-152.
38. Sugawara N, Yasui-Furukori N, Sato Y, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res. 2010;123:244-250.
39. Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2003;73:435-455.
40. Nisa H, Kono S, Yin G, et al. Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. BMC Cancer. 2010;10:274.
41. Teranishi M, Uchida Y, Nishio N, et al. Polymorphisms in genes involved in oxidative stress response in patients with sudden sensorineu-ral hearing loss and Meniere's disease in a Japanese population. DNA Cell Biol. 2012;31:1555-1562.
42. Maciel SS, Pereira Ada C, Silva GJ, Rodrigues M V, Mill JG, Krieger JE. Association between glutathione S-transferase polymorphisms and trig-lycerides and HDL-cholesterol. Atherosclerosis. 2009;206:204-208.
43. Di Pietro G, Magno LA, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol. 2010;6:153-170.
44. Zhang J, Liu H, Yan H, Huang G, Wang B. Null genotypes of GSTM1 and GSTT1 contribute to increased risk of diabetes mellitus: a meta-analysis. Gene. 2013;518:405-411.
45. Kropp S, Kern V, Lange K, et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci. 2005;17:227-231.
46. Pillai A, Parikh V, Terry AV Jr, Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res. 2007;41:372-386.